NEW YORK (GenomeWeb News) – Asterand today said that its BioSeek subsidiary will screen Amylin Pharmaceuticals' library of compounds to discover peptides with a potential for treating inflammatory conditions.
Under a one-year contract, BioSeek will apply its BioMap predictive human disease models to screen Amylin's library. The new deal builds on earlier similar agreements between the two firms involving peptide screening and related drug discovery activities.
The BioMap systems are cell-based models of human disease biology that are designed to replicate cell and pathway interactions as they are observed in human pharmacology and toxicology.